이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
CRISPR Therapeutics 관리
관리 기준 확인 3/4
CRISPR Therapeutics' CEO는 Sam Kulkarni, Dec2017 에 임명되었습니다 의 임기는 6.5 년입니다. 총 연간 보상은 $ 12.32M, 5.9% 로 구성됩니다. 5.9% 급여 및 94.1% 보너스(회사 주식 및 옵션 포함). 는 $ 24.72M 가치에 해당하는 회사 주식의 0.48% 직접 소유합니다. 24.72M. 경영진과 이사회의 평균 재임 기간은 각각 4.7 년과 5 년입니다.
주요 정보
Sam Kulkarni
최고 경영자
US$12.3m
총 보상
| CEO 급여 비율 | 5.9% |
| CEO 임기 | 6.6yrs |
| CEO 소유권 | 0.5% |
| 경영진 평균 재임 기간 | 4.8yrs |
| 이사회 평균 재임 기간 | 5.1yrs |
최근 관리 업데이트
Recent updates
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18
Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M
Aug 08Crispr Therapeutics' Continued Progress Warrants A Buy
Jul 25CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$12m | US$725k | -US$154m |
| Sep 30 2023 | n/a | n/a | -US$354m |
| Jun 30 2023 | n/a | n/a | -US$416m |
| Mar 31 2023 | n/a | n/a | -US$524m |
| Dec 31 2022 | US$21m | US$700k | -US$650m |
| Sep 30 2022 | n/a | n/a | -US$681m |
| Jun 30 2022 | n/a | n/a | -US$633m |
| Mar 31 2022 | n/a | n/a | US$312m |
| Dec 31 2021 | US$17m | US$670k | US$378m |
| Sep 30 2021 | n/a | n/a | US$412m |
| Jun 30 2021 | n/a | n/a | US$447m |
| Mar 31 2021 | n/a | n/a | -US$392m |
| Dec 31 2020 | US$9m | US$625k | -US$349m |
| Sep 30 2020 | n/a | n/a | -US$211m |
| Jun 30 2020 | n/a | n/a | US$20m |
| Mar 31 2020 | n/a | n/a | US$46m |
| Dec 31 2019 | US$16m | US$550k | US$67m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$200m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$10m | US$518k | -US$165m |
| Sep 30 2018 | n/a | n/a | -US$117m |
| Jun 30 2018 | n/a | n/a | -US$91m |
| Mar 31 2018 | n/a | n/a | -US$75m |
| Dec 31 2017 | US$7m | US$405k | -US$68m |
보상 대 시장: Sam 의 총 보상 ($USD 12.32M )은 US 시장( $USD 8.45M ).
보상과 수익: Sam 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Sam Kulkarni (46 yo)
6.6yrs
테뉴어
US$12,322,196
보상
Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as an Independent Non-Executive Director of Centessa Ph...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Chairman | 6.6yrs | US$12.32m | 0.48% $ 22.0m | |
| Chief Financial Officer | 1.3yrs | US$5.91m | 0.012% $ 540.3k | |
| General Counsel & Secretary | 7.2yrs | US$3.51m | 0.072% $ 3.3m | |
| Founder | no data | 데이터 없음 | 데이터 없음 | |
| Co-Founder & Scientific Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Scientific Founder & Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Scientific Founder | no data | 데이터 없음 | 데이터 없음 | |
| Scientific Founder & Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Scientific Founder & Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Chief Operating Officer | less than a year | 데이터 없음 | 0.016% $ 747.1k | |
| Head of Technical Operations | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Corporate Communications & Investor Relations | no data | 데이터 없음 | 데이터 없음 |
4.8yrs
평균 재임 기간
49yo
평균 연령
경험이 풍부한 관리: CRSP 의 관리팀은 경험 ( 4.7 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Chairman | 6.1yrs | US$12.32m | 0.48% $ 22.0m | |
| Co-Founder & Scientific Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Scientific Founder & Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Scientific Founder & Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Scientific Founder & Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Lead Independent Director | 4.1yrs | US$552.56k | 0.0024% $ 108.2k | |
| Independent Director | 9.3yrs | US$545.06k | 0.00032% $ 14.7k | |
| Independent Director | 5.1yrs | US$532.56k | 0% $ 0 | |
| Independent Director | 9.3yrs | US$542.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.1yrs | US$555.06k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$536.24k | 0% $ 0 |
5.1yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 이사회: CRSP 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.